BioInvent International AB (Nasdaq Stockholm: BINV) announced the resignation of Vincent Ossipow from its board of directors, effective September 2nd, 2025. The company thanked Ossipow for his service.
Ossipow served on the board from 2016 to 2020 and again from 2021 to 2025. He expressed pride in the company’s progress and confidence in its future direction. He specifically mentioned his support for the company’s renewed focus on clinical trials.
Leonard Kruimer, chairman of the board, echoed the company’s appreciation for Ossipow‘s leadership and expertise. He noted Ossipow‘s significant contributions during critical periods of growth and strategic change.
With Ossipow‘s departure, the board now comprises seven members. This remains in compliance with the company’s bylaws, ensuring the board retains its quorum and can continue its operations without interruption.
BioInvent is a clinical-stage biotechnology company headquartered in Lund, Sweden. It specializes in discovering and developing novel, first-in-class immune-modulatory antibodies for cancer treatment. The company has ongoing clinical trials, focusing on hematological cancers and solid tumors.
The company utilizes its proprietary F.I.R.S.T™ technology platform to identify both targets and the antibodies that bind to them. This technology drives its internal pipeline and supports collaborations with major pharmaceutical companies.
BioInvent generates revenue through research collaborations, licensing agreements, and contract antibody manufacturing. Its fully integrated manufacturing unit provides additional revenue streams. The company continues its research and development efforts in the field of immuno-oncology.
The company’s contact information for further inquiries was provided in the press release.
Related
